Investigational drug · Phase 2
AMT-253
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Melanoma, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AMT-253"
First trial start
2024
Jan 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AMT-253", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Melanoma
- Advanced Solid Tumors
Largest trials
Live from ClinicalTrials.gov: studies naming "AMT-253" as an intervention, largest first.
Multitude Therapeutics Inc.Industry
NCT06209580 · 96 participants (planned) · Start Jan 31, 2024 · Primary completion Apr 30, 2026
Drug: AMT-253 for injection · For: Malignant Melanoma; Advanced Solid Tumors
Sites: Beijing, China
Multitude Therapeutics (Australia) Pty LtdIndustry
NCT05906862 · 54 participants (planned) · Start Nov 6, 2023 · Primary completion Sep 30, 2026
Drug: AMT-253 · For: Advanced Solid Tumor
Sites: Sydney, Australia; Brisbane, Australia; Adelaide, Australia · 7 sites in all
- Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced TumorsStatus unknown
Beijing Immunochina Medical Science & Technology Co., Ltd.Industry
NCT05117138 · 39 participants (planned) · Start Jan 1, 2022 · Primary completion Dec 1, 2023
Drug: AMT-116 CAR-T cells; AMT-253 CAR-T cells · For: Melanoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations.
Lami I, Wiemer AJ · Drugs R D 2024
- A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.
Shi J, Jiao T, Guo Q, et al. · Cancer Res 2023
Also in development for Malignant Melanoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
- RAPA-201 Rapamycin Resistant T CellsRAPA-201 cellsPhase 22 trials
Rapa Therapeutics LLC · Malignant Melanoma, Malignant Melanoma With Metastasis, Malignant Melanoma Stage IIIc
- TCC1727Phase 22 trials
Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
- GM103Phase 21 trial
GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.